European Archives - Page 135 of 1169 - European Medical Journal

Rezivertinib Outperforms Gefitinib in NSCLC Treatment Study

A Phase III trial has shown that rezivertinib offers superior progression-free survival compared to gefitinib as a first-line treatment in EGFR-mutated locally advanced or metastatic non-small-cell lung cancer.

Combined Ultrasound Technique Reliable for Ruling Out N2 Disease in Patients with Lung Cancer

Study shows combined endobronchial ultrasound and endoscopic ultrasound (CUS) is a highly reliable tool for ruling out N2 disease in patients with PET-negative lung cancer.

Azithromycin Susceptibility of Oral Streptococci in Men Who Have Sex With Men

A recent randomised controlled trial came to the surprising conclusion that dual gonococcal treatment with azithromycin/ceftriaxone…

Self-Healing E-Skin Recovers in 10 Seconds, Transforming Biometric Wearables

A new self-healing E-Skin recovers within 10 seconds, enabling AI-assisted real-time health monitoring in extreme conditions.

Donal Brennan

Onc Now: Episode 11: The Obesity Cancer Connection

Donal Brennan shares insights on ovarian cancer surgery, obesity-related carcinogenesis, and innovations in patient care.

Daratumumab-Based Quadruplet Regimen Sets New Benchmark in Myeloma Treatment

A Phase III trial shows adding daratumumab to VRd enhances treatment response in transplant-ineligible multiple myeloma patients.

Antibiotic Resistance in Diabetes: New Research Reveals Concerning Trend

A recent study has uncovered a worrying link between diabetes and the rapid emergence of antibiotic resistance.

New Cambridge Study Reveals Vaccine Challenges for Immunocompromised Individuals

The study highlights the necessity of a third vaccination to detect neutralising activity, particularly against emerging Omicron subvariants.

Data

ABPI urges NHS to improve data access for pharma research

A new cross-industry report is calling for the UK’s NHS to design its health data infrastructure to meet the needs of pharma researchers.

Study Finds No Benefit of Drug Combination in Cirrhosis

Findings suggest that combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe complications in patients with decompensated cirrhosis.